Join Growin Stock Community!

Jazz pharmaceuticals plcJAZZ.US Overview

US StockHealthcare
(No presentation for JAZZ)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

JAZZ AI Insights

JAZZ Overall Performance

JAZZ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

JAZZ Recent Performance

-0.29%

Jazz pharmaceuticals plc

0.05%

Avg of Sector

-0.31%

S&P500

JAZZ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

JAZZ Key Information

JAZZ Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

JAZZ Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Price of JAZZ

JAZZ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

JAZZ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.79
PE Ratio (TTM)
-
Forward PE
8.42
PS Ratio (TTM)
2.74
PB Ratio
2.71
Price-to-FCF
8.85
METRIC
VALUE
vs. INDUSTRY
Gross Margin
88.21%
Net Margin
-8.35%
Revenue Growth (YoY)
4.88%
Profit Growth (YoY)
3.89%
3-Year Revenue Growth
7.21%
3-Year Profit Growth
9.08%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.79
PE Ratio (TTM)
-
Forward PE
8.42
PS Ratio (TTM)
2.74
PB Ratio
2.71
Price-to-FCF
8.85
Gross Margin
88.21%
Net Margin
-8.35%
Revenue Growth (YoY)
4.88%
Profit Growth (YoY)
3.89%
3-Year Revenue Growth
7.21%
3-Year Profit Growth
9.08%

  • When is JAZZ's latest earnings report released?

    The most recent financial report for Jazz pharmaceuticals plc (JAZZ) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JAZZ's short-term business performance and financial health. For the latest updates on JAZZ's earnings releases, visit this page regularly.

  • What is the operating profit of JAZZ?

    According to the latest financial report, Jazz pharmaceuticals plc (JAZZ) reported an Operating Profit of 254.54M with an Operating Margin of 21.25% this period, representing a growth of 33.43% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is JAZZ's revenue growth?

    In the latest financial report, Jazz pharmaceuticals plc (JAZZ) announced revenue of 1.2B, with a Year-Over-Year growth rate of 10.09%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does JAZZ have?

    As of the end of the reporting period, Jazz pharmaceuticals plc (JAZZ) had total debt of 5.41B, with a debt ratio of 0.46. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does JAZZ have?

    At the end of the period, Jazz pharmaceuticals plc (JAZZ) held Total Cash and Cash Equivalents of 1.39B, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does JAZZ go with three margins increasing?

    In the latest report, Jazz pharmaceuticals plc (JAZZ) achieved the “three margins increasing” benchmark, with a gross margin of 87.2%%, operating margin of 21.25%%, and net margin of 17%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess JAZZ's profit trajectory and future growth potential.

  • Is JAZZ's EPS continuing to grow?

    According to the past four quarterly reports, Jazz pharmaceuticals plc (JAZZ)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 3.34. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of JAZZ?

    Jazz pharmaceuticals plc (JAZZ)'s Free Cash Flow (FCF) for the period is 373.96M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2.94% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of JAZZ?

    The latest valuation data shows Jazz pharmaceuticals plc (JAZZ) has a Price-To-Earnings (PE) ratio of -30.05 and a Price/Earnings-To-Growth (PEG) ratio of -0.61. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.